Mechanism

How it works

Glutathione exerts its antioxidant effects primarily by donating electrons to neutralize free radicals and reactive oxygen species, becoming oxidized glutathione (GSSG) in the process, which is then recycled back to its reduced active form (GSH) by glutathione reductase using NADPH. It is an essential cofactor for glutathione peroxidase enzymes that detoxify lipid peroxides and hydrogen peroxide, and it conjugates with electrophilic toxins via glutathione S-transferases in the liver to facilitate their excretion. Glutathione also plays a critical role in maintaining the thiol redox state of proteins, modulating immune cell function, and supporting mitochondrial integrity.

Reported in research

Benefits

Potent antioxidant protection against oxidative stress and free radical damage
Enhanced hepatic detoxification of xenobiotics, heavy metals, and environmental toxins
Improved immune function including natural killer cell activity and T-lymphocyte proliferation
Skin brightening and reduction of hyperpigmentation by inhibiting melanin synthesis

Context, not a prescription

Dosing

Typical range: 600–1500 mg per session, 1–3 times per week (Intramuscular, Oral)
Cycle length: 4–8 weeks
Half-life: ~10 minutes (IV/IM); oral bioavailability is low without specialized formulations

Safety

Side effects & contraindications

Possible side effects

Mild injection site discomfort or bruising
Rare hypersensitivity or allergic reactions
Potential zinc depletion with long-term high-dose use
Nausea or gastrointestinal upset (oral forms)

Contraindications

Known hypersensitivity to glutathione or any component of the formulation
Use with caution in individuals undergoing chemotherapy, as antioxidant interference with oxidative cancer therapies is theoretically possible
Pregnancy and breastfeeding (insufficient safety data for high-dose parenteral use)

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

Users commonly report improved energy levels, reduced brain fog, enhanced skin clarity and tone, and generally feeling more resilient. Objective improvements in liver enzyme markers can be seen in clinical populations within 4–8 weeks.

How it works

Think of glutathione as the sponge in your body's kitchen — it soaks up the mess (free radicals and toxins) before they can damage the countertops (your cells and DNA). When the sponge gets full, special enzymes wring it out so it can be used again.

After injection, glutathione is absorbed directly into the bloodstream and taken up by cells throughout the body, especially in the liver. It boosts the liver's ability to filter the blood, supports the immune system's fighter cells, and helps keep skin tone even by slowing down pigment production.

What to expect

Some users report feeling increased energy and clarity within the first 1–2 sessions. Skin changes, if sought, typically become noticeable after 4–8 weeks of consistent use.

Week 1: Initial sessions establish baseline levels; some users notice a subtle boost in energy and sense of well-being shortly after administration.
Weeks 2–4: Antioxidant capacity builds up; some users begin noticing improved skin clarity, reduced fatigue, and better recovery from exercise or illness.
Weeks 4–8: More pronounced effects on skin tone and energy; liver health markers may begin improving in those with elevated baseline levels. Long-term maintenance dosing can be considered.

Good to know

Start with a lower dose (600 mg) to assess tolerance before moving to higher doses
Always use a clean injection technique or have injections administered by a trained professional

Staying safe

Mild soreness or redness at the injection site
Occasional nausea, especially with oral forms

Avoid if you have:

People currently undergoing cancer chemotherapy (consult oncologist first)
Pregnant or breastfeeding women
Individuals with known allergy to glutathione

Overview

Biochemically, repeat dosing increases erythrocyte GSH:GSSG ratios, reduces plasma F2-isoprostane levels (a marker of lipid peroxidation), and in clinical populations with hepatic disease, lowers ALT/AST enzyme levels. Peripheral blood mononuclear cell GSH levels correlate with improved lymphocyte proliferative responses. Skin melanin index measurements show statistically significant reductions in some RCTs after 8–12 weeks of parenteral administration.

How it works

GSH functions as both a direct sacrificial reductant and an enzymatic cofactor — analogous to both the fire extinguisher (direct quenching) and the sprinkler system (enzymatic defense network) of a building's fire suppression infrastructure, with NADPH serving as the water supply that keeps both operational.

Parenterally administered glutathione bypasses gastrointestinal degradation by gamma-glutamyltranspeptidase (GGT) and enters systemic circulation intact. Cellular uptake occurs via multidrug resistance-associated protein (MRP) transporters and organic anion transporters. Hepatocytes accumulate GSH for conjugation reactions in the smooth endoplasmic reticulum and mitochondria. Exogenous GSH also modulates lymphocyte function: it supports Th1 polarization, enhances natural killer (NK) cell cytotoxicity, and promotes dendritic cell antigen presentation. In melanocytes, GSH inhibits tyrosinase activity both by direct copper chelation at the enzyme's active site and by shifting DOPA oxidation toward phaeomelanin (lighter pigment) rather than eumelanin.

Onset & timeline

Following IM administration, peak plasma GSH concentrations are typically reached within 15–30 minutes. The plasma half-life is approximately 10 minutes due to rapid cellular uptake and enzymatic turnover. Tissue-level accumulation and measurable increases in erythrocyte GSH concentrations may persist for 24–48 hours post-injection, supporting a 2–3x weekly dosing frequency.

Days 1–3: Plasma and erythrocyte GSH levels rise acutely post-injection. Rapid hepatocyte uptake initiates enhanced Phase II conjugation activity. GSSG:GSH ratio in plasma begins to normalize in oxidatively stressed individuals.
Weeks 1–2: Cumulative increase in tissue GSH pools with 2–3x weekly dosing. Upregulation of Nrf2-mediated ARE genes (including endogenous GSH synthesis enzymes GCL and GSS) may begin as a secondary adaptive response. Subjective improvements in energy and cognitive clarity reported by many users.
Weeks 2–8: Sustained redox rebalancing leads to measurable reductions in oxidative stress biomarkers (8-OHdG, F2-isoprostanes). Hepatic detoxification capacity improves; liver enzyme normalization observed in clinical hepatitis and NAFLD studies. Skin melanin index begins to decline statistically around weeks 4–8 in dermatological studies.

Getting the most from it

Monitor serum zinc and copper levels every 8–12 weeks during long-term therapy; supplement zinc if levels decline below reference range
Administer IM injections slowly using a 23–25 gauge needle into the gluteal or deltoid muscle to minimize discomfort and local reactions
Avoid concurrent administration with hydrogen peroxide-generating compounds or oxidizing agents that could rapidly consume administered GSH before cellular uptake

Common side effects

Transient injection site erythema, induration, or discomfort — particularly with IM administration of higher-concentration formulations
Possible mild zinc depletion with prolonged high-dose therapy due to upregulation of metallothionein competing for zinc

Mechanism of action

Glutathione (GSH) is the predominant intracellular thiol antioxidant, maintained in its reduced form at concentrations of 1–10 mM intracellularly. Its antioxidant function depends on the GSH/GSSG redox couple, with glutathione peroxidases (GPx1–4) catalyzing the reduction of H2O2 and organic hydroperoxides at the expense of GSH. Oxidized GSSG is regenerated by glutathione reductase using NADPH derived from the pentose phosphate pathway. GSH also participates in glutaredoxin-mediated protein deglutathionylation, protecting critical protein cysteine residues from irreversible oxidation. In Phase II hepatic detoxification, glutathione S-transferases (GSTs) catalyze the conjugation of GSH with electrophilic substrates forming mercapturic acid derivatives for biliary or renal excretion. GSH modulates NF-κB and Nrf2 signaling pathways, influencing inflammatory gene expression and the antioxidant response element (ARE) transcriptional program. Mitochondrially, GSH (mt-GSH) is a critical determinant of organelle redox balance, protecting against permeability transition pore opening and cytochrome c release.

Parenterally administered glutathione bypasses gastrointestinal degradation by gamma-glutamyltranspeptidase (GGT) and enters systemic circulation intact. Cellular uptake occurs via multidrug resistance-associated protein (MRP) transporters and organic anion transporters. Hepatocytes accumulate GSH for conjugation reactions in the smooth endoplasmic reticulum and mitochondria. Exogenous GSH also modulates lymphocyte function: it supports Th1 polarization, enhances natural killer (NK) cell cytotoxicity, and promotes dendritic cell antigen presentation. In melanocytes, GSH inhibits tyrosinase activity both by direct copper chelation at the enzyme's active site and by shifting DOPA oxidation toward phaeomelanin (lighter pigment) rather than eumelanin.

Pharmacodynamics

Following IM administration, peak plasma GSH concentrations are typically reached within 15–30 minutes. The plasma half-life is approximately 10 minutes due to rapid cellular uptake and enzymatic turnover. Tissue-level accumulation and measurable increases in erythrocyte GSH concentrations may persist for 24–48 hours post-injection, supporting a 2–3x weekly dosing frequency.

Biochemically, repeat dosing increases erythrocyte GSH:GSSG ratios, reduces plasma F2-isoprostane levels (a marker of lipid peroxidation), and in clinical populations with hepatic disease, lowers ALT/AST enzyme levels. Peripheral blood mononuclear cell GSH levels correlate with improved lymphocyte proliferative responses. Skin melanin index measurements show statistically significant reductions in some RCTs after 8–12 weeks of parenteral administration.

Timeline

Days 1–3: Plasma and erythrocyte GSH levels rise acutely post-injection. Rapid hepatocyte uptake initiates enhanced Phase II conjugation activity. GSSG:GSH ratio in plasma begins to normalize in oxidatively stressed individuals.
Weeks 1–2: Cumulative increase in tissue GSH pools with 2–3x weekly dosing. Upregulation of Nrf2-mediated ARE genes (including endogenous GSH synthesis enzymes GCL and GSS) may begin as a secondary adaptive response. Subjective improvements in energy and cognitive clarity reported by many users.
Weeks 2–8: Sustained redox rebalancing leads to measurable reductions in oxidative stress biomarkers (8-OHdG, F2-isoprostanes). Hepatic detoxification capacity improves; liver enzyme normalization observed in clinical hepatitis and NAFLD studies. Skin melanin index begins to decline statistically around weeks 4–8 in dermatological studies.

Comparisons

Glutathione (IM/IV) — effectiveness High, safety Good, cost $$, Medium to use
Liposomal Glutathione (oral) — effectiveness Moderate, safety Excellent, cost $$, Low to use
N-Acetyl Cysteine (NAC) — oral GSH precursor — effectiveness Moderate, safety Excellent, cost $, Low to use

Adverse effects

Common:

Transient injection site erythema, induration, or discomfort — particularly with IM administration of higher-concentration formulations
Possible mild zinc depletion with prolonged high-dose therapy due to upregulation of metallothionein competing for zinc

Rare:

Anaphylactic or anaphylactoid reactions (<0.1% incidence; likely related to excipients or rapid administration rather than GSH itself)
Theoretical concern for reductive interference with platinum-based or anthracycline chemotherapy agents — documented in preclinical models but evidence in humans is mixed

Contraindications & risk mitigation

Contraindicated in:

Patients undergoing cisplatin or cyclophosphamide chemotherapy without oncological supervision — GSH may reduce cytotoxic efficacy by detoxifying reactive intermediates
Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency — impaired NADPH regeneration limits GSH recycling and may exacerbate hemolytic risk
Those with severe asthma — rare reports of bronchospasm with inhaled or IV glutathione formulations

Monitor serum zinc and copper levels every 8–12 weeks during long-term therapy; supplement zinc if levels decline below reference range
Administer IM injections slowly using a 23–25 gauge needle into the gluteal or deltoid muscle to minimize discomfort and local reactions
Avoid concurrent administration with hydrogen peroxide-generating compounds or oxidizing agents that could rapidly consume administered GSH before cellular uptake

Qué hace

Users commonly report improved energy levels, reduced brain fog, enhanced skin clarity and tone, and generally feeling more resilient. Objective improvements in liver enzyme markers can be seen in clinical populations within 4–8 weeks.

Cómo funciona

Think of glutathione as the sponge in your body's kitchen — it soaks up the mess (free radicals and toxins) before they can damage the countertops (your cells and DNA). When the sponge gets full, special enzymes wring it out so it can be used again.

After injection, glutathione is absorbed directly into the bloodstream and taken up by cells throughout the body, especially in the liver. It boosts the liver's ability to filter the blood, supports the immune system's fighter cells, and helps keep skin tone even by slowing down pigment production.

Qué esperar

Some users report feeling increased energy and clarity within the first 1–2 sessions. Skin changes, if sought, typically become noticeable after 4–8 weeks of consistent use.

Week 1: Initial sessions establish baseline levels; some users notice a subtle boost in energy and sense of well-being shortly after administration.
Weeks 2–4: Antioxidant capacity builds up; some users begin noticing improved skin clarity, reduced fatigue, and better recovery from exercise or illness.
Weeks 4–8: More pronounced effects on skin tone and energy; liver health markers may begin improving in those with elevated baseline levels. Long-term maintenance dosing can be considered.

Bueno saber

Start with a lower dose (600 mg) to assess tolerance before moving to higher doses
Always use a clean injection technique or have injections administered by a trained professional

Manteniéndose seguro

Mild soreness or redness at the injection site
Occasional nausea, especially with oral forms

Evitar si tienes:

People currently undergoing cancer chemotherapy (consult oncologist first)
Pregnant or breastfeeding women
Individuals with known allergy to glutathione

Descripción general

Biochemically, repeat dosing increases erythrocyte GSH:GSSG ratios, reduces plasma F2-isoprostane levels (a marker of lipid peroxidation), and in clinical populations with hepatic disease, lowers ALT/AST enzyme levels. Peripheral blood mononuclear cell GSH levels correlate with improved lymphocyte proliferative responses. Skin melanin index measurements show statistically significant reductions in some RCTs after 8–12 weeks of parenteral administration.

Cómo funciona

GSH functions as both a direct sacrificial reductant and an enzymatic cofactor — analogous to both the fire extinguisher (direct quenching) and the sprinkler system (enzymatic defense network) of a building's fire suppression infrastructure, with NADPH serving as the water supply that keeps both operational.

Parenterally administered glutathione bypasses gastrointestinal degradation by gamma-glutamyltranspeptidase (GGT) and enters systemic circulation intact. Cellular uptake occurs via multidrug resistance-associated protein (MRP) transporters and organic anion transporters. Hepatocytes accumulate GSH for conjugation reactions in the smooth endoplasmic reticulum and mitochondria. Exogenous GSH also modulates lymphocyte function: it supports Th1 polarization, enhances natural killer (NK) cell cytotoxicity, and promotes dendritic cell antigen presentation. In melanocytes, GSH inhibits tyrosinase activity both by direct copper chelation at the enzyme's active site and by shifting DOPA oxidation toward phaeomelanin (lighter pigment) rather than eumelanin.

Inicio y cronología

Following IM administration, peak plasma GSH concentrations are typically reached within 15–30 minutes. The plasma half-life is approximately 10 minutes due to rapid cellular uptake and enzymatic turnover. Tissue-level accumulation and measurable increases in erythrocyte GSH concentrations may persist for 24–48 hours post-injection, supporting a 2–3x weekly dosing frequency.

Days 1–3: Plasma and erythrocyte GSH levels rise acutely post-injection. Rapid hepatocyte uptake initiates enhanced Phase II conjugation activity. GSSG:GSH ratio in plasma begins to normalize in oxidatively stressed individuals.
Weeks 1–2: Cumulative increase in tissue GSH pools with 2–3x weekly dosing. Upregulation of Nrf2-mediated ARE genes (including endogenous GSH synthesis enzymes GCL and GSS) may begin as a secondary adaptive response. Subjective improvements in energy and cognitive clarity reported by many users.
Weeks 2–8: Sustained redox rebalancing leads to measurable reductions in oxidative stress biomarkers (8-OHdG, F2-isoprostanes). Hepatic detoxification capacity improves; liver enzyme normalization observed in clinical hepatitis and NAFLD studies. Skin melanin index begins to decline statistically around weeks 4–8 in dermatological studies.

Cómo aprovecharlo al máximo

Monitor serum zinc and copper levels every 8–12 weeks during long-term therapy; supplement zinc if levels decline below reference range
Administer IM injections slowly using a 23–25 gauge needle into the gluteal or deltoid muscle to minimize discomfort and local reactions
Avoid concurrent administration with hydrogen peroxide-generating compounds or oxidizing agents that could rapidly consume administered GSH before cellular uptake

Efectos secundarios comunes

Transient injection site erythema, induration, or discomfort — particularly with IM administration of higher-concentration formulations
Possible mild zinc depletion with prolonged high-dose therapy due to upregulation of metallothionein competing for zinc

Mecanismo de acción

Glutathione (GSH) is the predominant intracellular thiol antioxidant, maintained in its reduced form at concentrations of 1–10 mM intracellularly. Its antioxidant function depends on the GSH/GSSG redox couple, with glutathione peroxidases (GPx1–4) catalyzing the reduction of H2O2 and organic hydroperoxides at the expense of GSH. Oxidized GSSG is regenerated by glutathione reductase using NADPH derived from the pentose phosphate pathway. GSH also participates in glutaredoxin-mediated protein deglutathionylation, protecting critical protein cysteine residues from irreversible oxidation. In Phase II hepatic detoxification, glutathione S-transferases (GSTs) catalyze the conjugation of GSH with electrophilic substrates forming mercapturic acid derivatives for biliary or renal excretion. GSH modulates NF-κB and Nrf2 signaling pathways, influencing inflammatory gene expression and the antioxidant response element (ARE) transcriptional program. Mitochondrially, GSH (mt-GSH) is a critical determinant of organelle redox balance, protecting against permeability transition pore opening and cytochrome c release.

Parenterally administered glutathione bypasses gastrointestinal degradation by gamma-glutamyltranspeptidase (GGT) and enters systemic circulation intact. Cellular uptake occurs via multidrug resistance-associated protein (MRP) transporters and organic anion transporters. Hepatocytes accumulate GSH for conjugation reactions in the smooth endoplasmic reticulum and mitochondria. Exogenous GSH also modulates lymphocyte function: it supports Th1 polarization, enhances natural killer (NK) cell cytotoxicity, and promotes dendritic cell antigen presentation. In melanocytes, GSH inhibits tyrosinase activity both by direct copper chelation at the enzyme's active site and by shifting DOPA oxidation toward phaeomelanin (lighter pigment) rather than eumelanin.

Farmacodinamia

Following IM administration, peak plasma GSH concentrations are typically reached within 15–30 minutes. The plasma half-life is approximately 10 minutes due to rapid cellular uptake and enzymatic turnover. Tissue-level accumulation and measurable increases in erythrocyte GSH concentrations may persist for 24–48 hours post-injection, supporting a 2–3x weekly dosing frequency.

Biochemically, repeat dosing increases erythrocyte GSH:GSSG ratios, reduces plasma F2-isoprostane levels (a marker of lipid peroxidation), and in clinical populations with hepatic disease, lowers ALT/AST enzyme levels. Peripheral blood mononuclear cell GSH levels correlate with improved lymphocyte proliferative responses. Skin melanin index measurements show statistically significant reductions in some RCTs after 8–12 weeks of parenteral administration.

Cronología

Days 1–3: Plasma and erythrocyte GSH levels rise acutely post-injection. Rapid hepatocyte uptake initiates enhanced Phase II conjugation activity. GSSG:GSH ratio in plasma begins to normalize in oxidatively stressed individuals.
Weeks 1–2: Cumulative increase in tissue GSH pools with 2–3x weekly dosing. Upregulation of Nrf2-mediated ARE genes (including endogenous GSH synthesis enzymes GCL and GSS) may begin as a secondary adaptive response. Subjective improvements in energy and cognitive clarity reported by many users.
Weeks 2–8: Sustained redox rebalancing leads to measurable reductions in oxidative stress biomarkers (8-OHdG, F2-isoprostanes). Hepatic detoxification capacity improves; liver enzyme normalization observed in clinical hepatitis and NAFLD studies. Skin melanin index begins to decline statistically around weeks 4–8 in dermatological studies.

Comparaciones

Glutathione (IM/IV) — efectividad High, seguridad Good, costo $$, Medium de usar
Liposomal Glutathione (oral) — efectividad Moderate, seguridad Excellent, costo $$, Low de usar
N-Acetyl Cysteine (NAC) — oral GSH precursor — efectividad Moderate, seguridad Excellent, costo $, Low de usar

Efectos adversos

Comunes:

Transient injection site erythema, induration, or discomfort — particularly with IM administration of higher-concentration formulations
Possible mild zinc depletion with prolonged high-dose therapy due to upregulation of metallothionein competing for zinc

Raros:

Anaphylactic or anaphylactoid reactions (<0.1% incidence; likely related to excipients or rapid administration rather than GSH itself)
Theoretical concern for reductive interference with platinum-based or anthracycline chemotherapy agents — documented in preclinical models but evidence in humans is mixed

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Patients undergoing cisplatin or cyclophosphamide chemotherapy without oncological supervision — GSH may reduce cytotoxic efficacy by detoxifying reactive intermediates
Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency — impaired NADPH regeneration limits GSH recycling and may exacerbate hemolytic risk
Those with severe asthma — rare reports of bronchospasm with inhaled or IV glutathione formulations

Monitor serum zinc and copper levels every 8–12 weeks during long-term therapy; supplement zinc if levels decline below reference range
Administer IM injections slowly using a 23–25 gauge needle into the gluteal or deltoid muscle to minimize discomfort and local reactions
Avoid concurrent administration with hydrogen peroxide-generating compounds or oxidizing agents that could rapidly consume administered GSH before cellular uptake

Reference data

Specifications

Molecular formula: C10H17N3O6S
Molecular weight: 307.32 g/mol
Half-life: ~10 minutes (IV/IM); oral bioavailability is low without specialized formulations
Route: Intramuscular, Oral
Cycle length: 4–8 weeks
Storage: Store lyophilized or reconstituted vials refrigerated at 2–8°C (36–46°F). Protect from light. Use reconstituted solution within 24–48 hours. Do not freeze reconstituted product.
Legal status: Legal as a dietary supplement (oral) and compounded injectable in many countries; not FDA-approved as a drug. Available through compounding pharmacies with a prescription in the USA.

FAQ

Common questions

Does exogenous glutathione suppress endogenous synthesis through negative feedback?

This is a valid pharmacological concern. There is limited evidence of significant negative feedback on the rate-limiting enzyme gamma-glutamylcysteine synthetase (GCL) with therapeutic doses of exogenous GSH. In fact, some data suggest that restoration of GSH pools may actually support Nrf2 signaling and upregulate endogenous synthesis genes. Nonetheless, cycling with GSH precursors (NAC, glycine) is a reasonable strategy for long-term protocols.

What is the evidence base for parenteral glutathione in liver disease?

Several small RCTs and open-label trials (notably Vendemiale et al., 1989 in Scandinavian Journal of Gastroenterology; and more recent Italian trials in NAFLD patients) have demonstrated reductions in ALT, AST, and oxidative stress markers with IV/IM glutathione at doses of 300–600 mg/day for 4 weeks. Evidence is promising but limited by small sample sizes and lack of large multicenter RCTs. It remains off-label for hepatic indications in most countries.

What is the evidence level?

This compound is classified as Limited human data. Some human data exists but trials are small, short-term, or not yet replicated.

Research

Research & sources

Limited human

Current evidence for Glutathione is rated as Limited human data. Limited human data is available.

1. Glutathione: overview of its protective roles, measurement, and biosynthesis (2009) — Molecular Aspects of Medicine. doi:10.1016/j.mam.2008.08.006
2. Effect of oral glutathione supplementation on body stores of glutathione (2015) — European Journal of Nutrition. doi:10.1007/s00394-014-0706-z
3. Glutathione and its antiaging and antimelanogenic effects (2017) — Clinical, Cosmetic and Investigational Dermatology. doi:10.2147/CCID.S128999
4. Intravenous glutathione in the treatment of early Parkinson's disease (1996) — Progress in Neuro-Psychopharmacology and Biological Psychiatry. doi:10.1016/S0278-5846(96)00084-2

Explore

Often discussed alongside

BPC-157 · healing